Dr. Naga Chalasani, MD
Claim this profileIndiana University
Studies Nonalcoholic Steatohepatitis
Studies Non-alcoholic Fatty Liver Disease
7 reported clinical trials
12 drugs studied
Affiliated Hospitals
Clinical Trials Naga Chalasani, MD is currently running
Biomarker Screening
for Liver Cancer
The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or patients with chronic hepatitis B infection. Eligible patients will be randomized in a 1:1 fashion to Arm A using semi-annual ultrasound and AFP-based screening or Arm B using semi-annual screening using GALAD alone. Randomization will be stratified by sex, enrolling site, Child Pugh class (A vs. B), and HCC etiology (viral vs. non-viral). Patients will be recruited from 15 sites (mix of tertiary care and large community health systems) over a 3-year period, and the primary endpoint of the phase IV trial, reduction in late-stage HCC, will be assessed after 5.5 years.
Recruiting3 awards Phase 44 criteria
Non-alcoholic Fatty Liver Disease
for People with HIV
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. NAFLD is the most common liver disease in US adults and the second leading cause for liver transplantation in the US. The natural history of NAFLD in the general population has been well described, with those with non-alcoholic fatty liver (NAFL, or simple steatosis) destined to have rare incidence of hepatic events compared to those with non-alcoholic steatohepatitis (NASH), who are at high risk for future development of cirrhosis, liver cancer and liver failure. The NASH Clinical Research Network (NASH CRN) was established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2002, through the mechanism of RFA-DK-01-025, to further the understanding of diagnosis, mechanisms, progression and therapies of NASH. The NASH CRN effort has resulted in numerous seminal studies in the field. However, NASH CRN studies have systematically excluded persons living with HIV (PLWH), as NAFLD in these persons was thought to be different from that in the general population due to HIV, ART, concomitant medications, and co-infections. This has resulted in major knowledge gaps regarding NAFLD in the setting of HIV. This ancillary study of NAFLD and NASH in Adults with HIV (HIV NASH CRN), HNC 001 goal is to examine the prevalence of hepatic steatosis and NAFLD in a large, multicenter, and multiethnic cohort of PLWH (Steatosis in HIV Study)
Recruiting1 award N/A3 criteria
More about Naga Chalasani, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Naga Chalasani, MD has experience with
- Omega-3 Fatty Acid (DHA EE)
- Vitamin E [(all-rac)-α-tocopheryl Acetate]
- No Investigational New Treatment
- Oncoguard™ Liver Test
- Standard Of Care CT/MRI Imaging
- Study CT/MRI Imaging
Breakdown of trials Naga Chalasani, MD has run
Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease
HIV (Human Immunodeficiency Virus)
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Naga Chalasani, MD specialize in?
Naga Chalasani, MD focuses on Nonalcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease. In particular, much of their work with Nonalcoholic Steatohepatitis has involved treating patients, or patients who are undergoing treatment.
Is Naga Chalasani, MD currently recruiting for clinical trials?
Yes, Naga Chalasani, MD is currently recruiting for 3 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Naga Chalasani, MD has studied deeply?
Yes, Naga Chalasani, MD has studied treatments such as Omega-3 fatty acid (DHA EE), Vitamin E [(all-rac)-α-tocopheryl acetate], No Investigational New Treatment.
What is the best way to schedule an appointment with Naga Chalasani, MD?
Apply for one of the trials that Naga Chalasani, MD is conducting.
What is the office address of Naga Chalasani, MD?
The office of Naga Chalasani, MD is located at: Indiana University, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.